Doxorubicin Hydrochloride Liposome is named as a drug or biological intervention in 4 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Hansoh BioMedical R&D Company (1), Jiangsu HengRui Medicine Co., Ltd. (1) and Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1). Registered phases: Phase 3 and Phase 1/2. Conditions studied include Ovarian Cancer; Platinum-sensitive Recurrent Ovarian Cancer; Diffuse Large B-Cell Lymphoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06828354 | A Study of SHR-A1811 in Subjects With Ovarian Cancer (ClinicalTrials.gov ↗) Ovarian Cancer |
Phase 3 | Recruiting |
| NCT06840002 | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (ClinicalTrials.gov ↗) Ovarian Cancer |
Phase 1/2 | Recruiting |
| NCT07821606 | Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer (ClinicalTrials.gov ↗) Platinum-sensitive Recurrent Ovarian Cancer |
Phase 3 | Not yet open |
| NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) Diffuse Large B-Cell Lymphoma |
Phase 1/2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 2 |
| Platinum-sensitive Recurrent Ovarian Cancer | 1 |
| Diffuse Large B-Cell Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Hansoh BioMedical R&D Company | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 1 |
| Register | Doxorubicin Hydrochloride Liposome trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Doxorubicin Hydrochloride Liposome works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Doxorubicin Hydrochloride Liposome (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.